Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
124 studies found for:    "Expanded Access" [STUDY-TYPES] | Open Studies
Show Display Options
Download search resultsDownload the search results for:
"Expanded Access" [STUDY-TYPES] | Open Studies (124 records)
Download Content:
zip file readers with free trial periods: WinZip and PKZip
Rank Status Study
1 Available Expanded Access With ABT-888 (Veliparib) to Treat Metastatic Breast Cancer
Conditions: Metastatic Breast Cancer With BRCA 1 or BRCA 2 Genetic Mutation;   Triple-Negative Breast Cancer
Interventions: Drug: Veliparib;   Drug: Cisplatin;   Drug: Vinorelbine
2 Available Levosimendan Compassionate Use in Pediatric Patients With Advanced Decompensated Heart Failure
Condition: Heart Decompensation
Intervention: Drug: Levosimendan
3 Available A Multicenter, Multi-national Open-label Program to Provide BMN 190 to Patients Diagnosed With CLN2 Disease
Condition: CLN2 Disease
Intervention: Drug: BMN190, recombinant human tripeptidyl peptidase-1 (rhTPP1)
4 Available Expanded Access Program of Ultratrace Iobenguane I131 for Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma
Conditions: Pheochromocytoma;   Paraganglioma
Intervention: Drug: Ultratrace Iobenguane I131
5 Available Therasphere for Unresectable Primary or Secondary Liver Neoplasia
Conditions: Liver Cancer;   Liver Neoplasms;   HepatoCellular Carcinoma
Intervention: Device: TheraSphere Treatment
6 Available Expanded Access Protocol of Patisiran for Patients With Hereditary ATTR Amyloidosis (hATTR)
Conditions: TTR-mediated Amyloidosis;   Amyloidosis, Hereditary;   Amyloid Neuropathies, Familial;   Familial Amyloid Polyneuropathies;   Amyloid Neuropathies;   Amyloidosis, Hereditary, Transthyretin-Related
Intervention: Drug: patisiran (ALN-TTR02)
7 Available The Multi-Center Study of Shear Wave Elastography on Thyroid Nodules
Condition: Thyroid Nodules
Intervention: Device: SWE
8 Available Expanded Access of Omegaven IV Fat Emulsion to Infants and Children With PNALD
Condition: Total Parenteral Nutrition-induced Cholestasis
Intervention: Drug: Omegaven IV lipid emulsion
9 Available Expanded Access Use of Omegaven® in the Treatment of Parenteral Nutrition Induced Liver Injury in Children
Condition: Parenteral Nutrition-Associated Liver Disease
Intervention: Drug: Omegaven
10 Available cliniMACs HUD for T Cell Depletion
Condition: x Linked Combined Immunodeficiency
Intervention: Device: CliniMACs
11 Available Rivaroxaban in Mechanical Valves: RIMV Study
Condition: Thromboembolism
Intervention: Drug: Rivaroxaban
12 Available A Phase I Study of DM-CHOC-PEN in Pediatric and Adolescent Subjects With Advanced Cancers
Condition: Document Safety for DM-CHOC-PEN in Pediatric and Adolescent Subjects With Advanced Cancer
Intervention: Drug: 4-Demethyl-4-cholesteryloxycarbonylpenclomedine
13 Available Expanded Access Program (EAP) for Nusinersen in Participants With Infantile-onset (Consistent With Type 1) Spinal Muscular Atrophy (SMA)
Condition: Infantile-onset Spinal Muscular Atrophy (SMA)
Intervention: Drug: nusinersen
14 Available Early Patient Access Treatment Use Protocol CA204-220
Condition: Multiple Myeloma
Interventions: Drug: Elotuzumab;   Drug: Lenalidomide;   Drug: Dexamethasone
15 Available Compassionate Use of SOM230 for Hyperinsulinemic/Hypoglycemia
Condition: Congenital Hyperinsulinism
Intervention: Drug: Pasireotide
16 Available C11 Sodium Acetate PET/CT Imaging of PCa
Condition: Prostate Cancer
Intervention: Drug: Carbon-11 Sodium Acetate
17 Available Open-label Evaluation of Polymyxin B Hemoperfusion for Septic Shock
Conditions: Septic Shock;   Endotoxemia
Intervention: Device: TORAYMYXIN PMX-20R
18 Available Crizotinib Expanded Access Protocol For ROS1 Positive NSCLC
Conditions: Neoplasms;   Carcinoma, Non-Small-Cell Lung
Intervention: Drug: crizotinib
19 Available Study of Allogeneic EBV-CTLs in EBV-Associated Viremia or Malignancies
Conditions: Epstein-Barr Virus-Associated Lymphoproliferative Disorder;   Epstein-Barr Virus Lymphoma;   Epstein-Barr Virus-Related Post-Transplant Lymphoproliferative Disorder;   Epstein-Barr Virus-Associated Viremia
Intervention: Biological: Epstein-Barr Virus Cytotoxic T Lymphoctyes (EBV-CTLs)
20 Available Expanded Access Program for Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis
Condition: Multiple Sclerosis
Intervention: Drug: Ocrelizumab

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.